抗TIF1-γ自身抗体:肿瘤自身抗原的警示信号
本综述概述了抗转录中介因子1γ(TIF1-γ)自身抗体的生理背景及其与肿瘤发生的病理生理联系。成人中抗TIF1-γ抗体对肿瘤相关皮肌炎(DM)具有高敏感性和特异性,可用于诊断和肿瘤风险分层。TIF1-γ在肿瘤中可发挥抑癌或促癌作用,其突变或杂合性缺失可能产生新抗原刺激自身抗体生成,进而交叉反应导致肌肉和皮肤损伤。
要点
- 抗TIF1-γ抗体对成人肿瘤相关DM诊断具有高敏感性和特异性。
- 抗TIF1-γ抗体有助于肿瘤风险分层。
- 抗TIF1-γ抗体应视为潜在肿瘤的警示信号。
核心结论
- 抗TIF1-γ自身抗体与成人肿瘤相关DM稳健关联,应视为潜在肿瘤自身抗原的警示信号。
- 抗TIF1-γ抗体检测对成人肿瘤相关DM具有高敏感性和特异性,可用于诊断和肿瘤风险分层。
研究设计与样本
- 本文为综述,旨在概述TIF1-γ的生理背景并探讨抗TIF1-γ抗体与肿瘤发生的病理生理联系。
主要发现
- TIF1-γ是一种普遍存在的蛋白,参与包括TGF-β信号在内的多种生物学通路。
- 在癌症中,TIF1-γ根据细胞背景和癌症阶段可发挥抑癌或促癌作用。
- DM患者肌肉和皮肤组织中TIF1-γ表达增加。
- 恶性肿瘤组织中TIF1-γ等位基因的突变或杂合性缺失可能导致肿瘤特异性新抗原表达,刺激自身抗体产生。
- 新形成的自身抗体被假设与肌肉和皮肤抗原交叉反应,驱动DM发生。
临床怎么用
- 检测抗TIF1-γ自身抗体有助于成人DM的诊断和肿瘤风险分层。
- 抗TIF1-γ抗体阳性应提醒医生排查潜在肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-transcription intermediary factor 1 (TIF1)-γ autoantibodies are robustly linked with cancer-associated DM in adults. This review aims to give an overview of the physiological context of TIF1-γ and to determine whether there is a pathophysiological link between anti-TIF1-γ autoantibodies and the occurrence of cancer. Detection of anti-TIF1-γ autoantibodies has a high sensitivity and specificity for cancer-associated DM in adults and is therefore useful for both diagnosis and cancer risk stratification. The function of the autoantigen, TIF1-γ, may provide insight into the mechanism behind this association. TIF1-γ is a ubiquitously present protein involved in various biological pathways, including TGF-β signalling. In cancer, it can act either as a tumour suppressor or promoter, depending on the cellular context and cancer stage. Evolving data provide pathophysiological insights, linking anti-TIF1-γ autoantibodies to both the anti-tumour response and to muscle and skin damage. TIF1-γ expression is increased in muscle and skin tissue of patients with DM. Mutations or loss-of-heterozygosity in TIF1-γ alleles in malignant tissue may result in the expression of tumour-specific neo-antigens stimulating autoantibody production. The newly formed autoantibodies are hypothesized to cross-react with antigens in muscle and skin, driving the development of DM. Based on the current evidence, anti-TIF1-γ autoantibodies should be considered warning lights of a potential tumour autoantigen and should alert the physician to the possibility of an underlying cancer.
引用
- De Vooght J, Vulsteke JB, De Haes P, et al. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen. Rheumatology (Oxford). 2020. PMID: 31883334. doi:10.1093/rheumatology/kez572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。